Total Funding
61
48
Total FundingSeries B raised
Growth Score
-13 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
15193
Charm Therapeutics designs and develops small-molecule therapeutics that target the interaction between menin and the KMT2A protein.
- Laksh Aithani: Co-Founder, CEO, and Board MemberPast Role: Exscientia, Machine Learning Engineer
- David Baker: Scientific Co-Founder
About the Company
Charm Therapeutics designs and develops a new generation of small-molecule therapeutics that target the interaction between menin and the KMT2A protein, a key driver of acute myeloid leukemia (AML), using its proprietary AI-powered platform called DragonFold. The company’s lead program is a menin inhibitor optimized to maintain activity against all
known clinical resistance mutations while minimizing safety and drug-interaction risks. Charm Therapeutics employs protein-ligand co-folding intelligence to inform molecular design, advancing its pipeline from preclinical stages toward the clinic.
